Repairing the Engine vs. Revving It: SS-31, MOTS-c, and the "Exercise in a Bottle" Molecule

TL;DR

• Three compounds, three different jobs - SS-31 repairs the membrane scaffold, MOTS-c signals for new mitochondria, SLU-PP-332 forces the build at the receptor.
• SS-31 binds cardiolipin directly - cell-permeable, no surface receptor, characterised in Journal of Biological Chemistry in 2020.
• Its FDA accelerated approval covers Barth syndrome only - September 2025, on TAZPOWER, a crossover trial in 12 genetically confirmed patients.
• SS-31's broader record is a record of misses - MMPOWER-3 failed its co-primary endpoints, as did trials in dry AMD and heart failure.
• MOTS-c plugs in at AMPK - upstream of PGC-1α and ERR; strong in mice, with human data so far about endogenous MOTS-c rising with exercise rather than about injecting it.
• Vivre does not offer SLU-PP-332 - rodent-only, no human data, and a real mechanistic cancer concern because ERRα is active in energy-hungry tumours.

Evidence-tiered; primary literature only. Educational content, not medical advice or a treatment claim. The compounds discussed are investigational; one is FDA-approved for a single rare disease only, and the others are not approved for energy, performance, or anti-aging use. Doses and protocols are deliberately omitted and are a physician determination.

Updated August 2026: names the approved SS-31 product (FORZINITY, Stealth BioTherapeutics) and states the size and limits of the TAZPOWER evidence base behind its accelerated approval.

---

"Repair your mitochondria" has become one of the most-repeated phrases in longevity content - and one of the least precise. People who feel persistently tired hear it and reasonably assume there's a compound that simply recharges them. The more interesting truth is that the compounds being studied here don't all do the same thing. Some try to repair the structure of a damaged engine. Others try to signal the body to build more engines. And one tries to flip the master switch directly - which is exactly why it isn't ready for anyone.

The cleanest way to understand the three most-discussed mitochondrial compounds - SS-31, MOTS-c, and SLU-PP-332 - is to first look at how a cell actually makes energy, and then see where each one acts.

How a cell actually makes energy (in one paragraph)

Inside each mitochondrion is a folded inner membrane, and embedded in it is the electron transport chain - the assembly line that produces ATP, the cell's energy currency. That membrane's structure is held together in part by a specialised fat called cardiolipin. When cardiolipin is damaged by age, oxidative stress, or disease, the inner membrane unfolds, the transport chain runs inefficiently, ATP output drops, and the leaky chain throws off more reactive oxygen species (free radicals) - which damages cardiolipin further. It's a doom loop: less energy, more damage, less energy.

That single picture explains the entire split between these three compounds. One targets the structure (cardiolipin and the membrane). The other two target the signalling that tells the cell to make more and better mitochondria.

SS-31: repairing the scaffold

SS-31 (elamipretide) is a synthetic four-amino-acid peptide that does something unusual for a peptide - it doesn't dock onto a surface receptor. It is cell-permeable: it penetrates the cell, travels to the inner mitochondrial membrane, and binds cardiolipin reversibly and directly, stabilising it. By propping up the scaffold that the electron transport chain sits on, it helps the membrane stay intact, which in models translates to more efficient ATP production and less oxidative leakage. The cardiolipin-binding mechanism is well-characterised in primary biophysics literature (Mitchell and colleagues, Journal of Biological Chemistry, 2020).

So SS-31 isn't an energy booster in the caffeine sense. It's closer to a structural repair agent for the engine itself.

Here is the part most promotional pages leave out, and it matters more than the mechanism. SS-31 has been through real human trials, and its record is mixed. In September 2025 the FDA granted accelerated approval to FORZINITY (elamipretide HCl), marketed by Stealth BioTherapeutics - to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg. Barth syndrome is an ultra-rare X-linked disorder caused by mutations in the tafazzin (TAZ) gene, which leaves cells short of usable cardiolipin - the exact molecule SS-31 binds. Around 150 individuals are known and diagnosed in the US, primarily males (a diagnosis count, not a prevalence estimate). That makes FORZINITY the first FDA-approved therapy for a mitochondrial disease - a genuine milestone, and a narrow one.

The evidence behind it deserves to be stated plainly, because the headline travels further than the trial. The approval rested on TAZPOWER, a randomised, double-blind, placebo-controlled crossover trial in 12 genetically confirmed patients. Knee-extensor strength gains were not seen during the randomised phase; they emerged during the open-label extension (8 patients followed through week 168). Accelerated approval also means confirmatory evidence is still owed. Twelve patients, with the signal appearing outside the blinded comparison, is a limited evidence base by any standard - which is defensible for an ultra-rare disease with no alternative, and is not the same thing as a robustly demonstrated effect.

Three distinctions worth holding onto, and the reason we wrote a separate piece on the question - is SS-31 FDA-approved? - because it is the single most misread fact in this category:

• Approved for a rare genetic disease is not evidence it works for aging. Barth syndrome is a cardiolipin deficiency caused by a single gene defect. Ordinary ageing is not that.
• "Reviewed" and "accelerated approval" are not the same as a finished efficacy story. Confirmatory work is still outstanding.
• The approved pharmaceutical product and the same-named research chemical are not the same thing. A prescription product with a defined identity, purity and label is a different object from a vial sold under the "SS-31" name.

In its broader trials SS-31 has repeatedly missed the mark: the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy failed its co-primary endpoints (the six-minute walk test and a fatigue score), and trials in dry age-related macular degeneration and heart failure also did not hit their primary endpoints.

There's a coherent reading of that pattern, and it's an honest one: SS-31 may do the most where the mitochondria are genuinely, structurally damaged, and comparatively little where they're already healthy. Propping up a scaffold helps most when the scaffold is failing. For a healthy person seeking "more energy," the realistic expectation should be modest, not transformative - and any use outside Barth syndrome is off-label and investigational. On the safety side, the trial record is reassuring as far as it goes: the most common reported effect was injection-site reaction, with no major safety signals highlighted - but "well-tolerated" is not the same as "proven to work" for the use most people are imagining.

MOTS-c: signalling the body to build more engines

If SS-31 repairs an existing engine, MOTS-c is a message that tells the cell to build new ones. It's a small peptide encoded within mitochondrial DNA itself, released when cells are under metabolic stress - the same kind of stress that exercise and fasting create. Its headline action is to activate AMPK, the cell's master energy-sensing pathway.

This is where the whiteboard pathway becomes useful, because it's a clean cascade:

• Exercise → metabolic stress → ATP drops → AMPK activation. Your energy reserve falls, and AMPK is the sensor that notices.
• AMPK → PGC-1α. AMPK turns up PGC-1α, the master regulator of mitochondrial production.
• PGC-1α → ERR (estrogen-related receptors). These receptors switch on the relevant genes.
• ERR → the outputs: mitochondrial biogenesis (more mitochondria), increased fatty-acid oxidation (fat burning), angiogenesis (new blood vessels), and improved muscular endurance.

MOTS-c plugs in near the top of that chain, at AMPK - it nudges the whole cascade the way a workout would, which is why it's often called an exercise mimetic. In preclinical work this is genuinely impressive: MOTS-c improved metabolic health and insulin sensitivity and reduced diet-induced obesity in mice (Lee and colleagues, Cell Metabolism, 2015), and late-life MOTS-c treatment improved physical capacity in aged mice while exercise was shown to raise the body's own MOTS-c in humans (Reynolds and colleagues, Nature Communications, 2021).

The honest limit: the strong, specific data are preclinical (mouse), and the human evidence is about the body's endogenous MOTS-c rising with exercise - not about injecting it. Controlled human outcome trials of exogenous MOTS-c administration remain pending. It's a compelling mechanism with an incomplete clinical story, and it should be described that way.

One useful correction to a common claim while we're here. Activating "energy" pathways is sometimes assumed to be uniformly cancer-promoting, but the MOTS-c picture is more nuanced than the headline. In ovarian cancer specifically, lower MOTS-c levels were associated with worse prognosis, and exogenous MOTS-c actually suppressed tumour growth in cell and mouse models (Yin and colleagues, Advanced Science, 2024). That's a single preclinical study, not a reason to draw conclusions - but it's a reminder that the lazy "all mitochondrial activators feed cancer" line doesn't survive contact with the actual literature. The real cancer concern in this space attaches to the next compound.

SLU-PP-332: flipping the master switch directly - and why Vivre doesn't offer it

Look back at the pathway. MOTS-c acts upstream, at AMPK, and lets the cascade flow down to ERR. SLU-PP-332 skips the line entirely and acts directly on ERRα - it's a synthetic ERR agonist that binds the receptor itself and switches on the downstream genes for biogenesis, fat-burning, and endurance without the upstream stimulus. In mice, it increased endurance, raised energy expenditure, and improved fat metabolism - which is why it picked up the "exercise in a bottle" nickname.

Two facts should stop that nickname cold for any prospective human user:

• It is mouse-only. SLU-PP-332 is a synthetic small molecule (not a peptide), studied in rodents, with no human data. "Exercise in a bottle" is a description of mouse experiments, not a product.
• The cancer concern is real and mechanistic. ERRα is also active in several cancer cell types precisely because tumours are energy-hungry. Pushing that master switch hard, for a long time, is exactly the kind of stimulus you would not want to apply blindly - especially in anyone with an undetected malignancy.

Vivre does not offer SLU-PP-332. It belongs in this article only so the science is complete and so the "Mitochondrial Trinity" marketing that circulates online - SS-31 + MOTS-c + SLU-PP-332 run on a fixed weekly schedule - can be named for what it is: a biohacker construct, not a validated protocol. There are no combination or sequencing trials behind it. The related online claim that MOTS-c "only works if SS-31 runs first" is likewise a plausible-sounding hypothesis with no combination study behind it, not an established rule.

So how do these actually relate?

The cleanest mental model:

• SS-31 repairs the mitochondrial scaffold (structural, cardiolipin-level).
• MOTS-c signals the body to build more and better mitochondria (metabolic, upstream at AMPK).
• SLU-PP-332 forces the build directly at the receptor (and is not something to use outside controlled research).

That structural-vs-signalling distinction is a real one, and it's why SS-31 and MOTS-c are sometimes discussed as complementary - one tends the existing engines while the other encourages new ones. But "complementary mechanisms" is a reason to be interested, not a finished protocol. Different mechanisms do not automatically mean additive benefit or additive safety; combinations need their own trials, and those don't yet exist here.

The honest limits (the part most articles skip)

• The evidence tiers are very different across the three. SS-31 has real human trials but a mixed record and an accelerated approval for one ultra-rare disease only, resting on a 12-patient study; everything else is off-label. MOTS-c is strong in mice with an incomplete human story. SLU-PP-332 is mouse-only with a real cancer concern. Treating them as interchangeable "mito peptides" erases exactly the distinctions that matter.
• "More energy" is the wrong frame for a healthy person. The mechanism that helps a damaged system may do very little in a healthy one. Honest expectations beat marketing.
• This is a measure-don't-guess area. Mitochondrial function isn't read off how you feel; it's approached through markers like lactate response, lipid-peroxidation markers, fasting insulin, and functional capacity (think VO₂max / Zone-2 work), interpreted by a clinician. Chasing a "mito stack" without a baseline is guessing.
• No doses or cycles here, on purpose. The schedules and "trinity" timings that circulate online come from social media, not primary literature. Whether any of this is appropriate, and in what form, is a physician determination made against your actual bloodwork.

The bigger point

The science here is genuinely exciting - the idea that we can either repair the cell's energy machinery or coax it to rebuild is a real frontier. But the same excitement is what makes this area so easy to oversell. The useful version of "repair your mitochondria" isn't a vial; it's a question answered with data: is there actually a structural or metabolic problem to address, and what does the evidence - at its real weight - support doing about it?

If you're exploring this seriously, the first step isn't a compound. It's a baseline you can measure and a physician who will read this evidence honestly - investigational where it's investigational, approved only where it's approved - and decide what, if anything, fits.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore SS-31.

Related reading

• Mitochondria and aging: why your cellular engines matter · NAD⁺ vs NMN vs NR
• Is SS-31 FDA-approved? - what the Barth syndrome approval does and does not cover
• MOTS-C, explained in depth - the exercise-mimetic peptide on its own
• Part of The Complete Guide to Mitochondria & Longevity

---

Educational content. Not medical advice and not a treatment claim. SS-31 (elamipretide) holds FDA accelerated approval only as FORZINITY for Barth syndrome; any other use, and any use of MOTS-c, is investigational and physician-supervised. SLU-PP-332 has no human data and is not offered by Vivre. Conditions named appear here as research context, not established indications. For Malaysia-facing care, disease and treatment claims are subject to MAB requirements.

Primary references

• Mitchell W, Ng EA, Tamucci JD, et al. The mitochondrial-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. J Biol Chem. 2020;295(21):7452–7469. (PMID 32554501)
• US Food and Drug Administration: accelerated approval of FORZINITY (elamipretide HCl), Stealth BioTherapeutics, September 2025 - to improve muscle strength in adult and paediatric patients with Barth syndrome weighing ≥30 kg; TAZPOWER randomised, double-blind, placebo-controlled crossover trial (n=12) with open-label extension (n=8 through week 168).
• Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. 2023;101(3):e238–e252.
• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.
• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470.
• Yin Y, et al. Mitochondrial-derived peptide MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Adv Sci. 2024;11(43):e2405620.
• Billon C, Sitaula S, Banerjee S, et al. Synthetic ERR agonist (SLU-PP-332) increases mitochondrial function and exercise capacity in mice. (ERRα-agonist preclinical pharmacology - note: rodent-only, no human data.)